RTP Mobile Logo
Submitted by web@researchtop... on Thu, 06/06/2019 - 09:31
ONUL117

Introduction

Track 1: Spectrum of DNA repair gene mutations in prostate, pancreatic and breast cancer
Track 2: Prevalence of DNA repair gene mutations in ovarian cancer
Track 3: Optimal approach to the use of PARP inhibitors for patients with BRCA mutations

Module 1: PARP Inhibition as a Therapeutic Strategy — Ovarian Cancer at the Vanguard

Track 4: Molecular profiling for patients with ovarian cancer
Track 5: Genetic testing algorithms for detecting mutations that may predict benefit from PARP inhibitors
Track 6: Choice of first-line therapy for patients with ovarian cancer and germline BRCA mutations
Track 7: Efficacy of PARP inhibitors in patients with platinum-sensitive, relapsed ovarian cancer
Track 8: Perspective on the potential role of PARP inhibitors for recurrent prostate cancer

Module 2: Current and Emerging Role of PARP Inhibitors in Metastatic Breast Cancer

Track 9: Activity of PARP inhibitors in patients with breast cancer and somatic versus germline BRCA mutations; effect of hormone receptor status on activity of PARP inhibitors
Track 10: Efficacy of PARP inhibitors in patients with triple-negative or HER2-positive metastatic breast cancer
Track 11: Comparison of olaparib to talazoparib for patients with advanced breast cancer and germline BRCA mutations

Module 3: Gastrointestinal Cancer and PARP Inhibition — What We Know and What We Don’t

Track 12: Perspective on the potential use of PARP inhibitors for patients with metastatic gastroesophageal cancer and BRCA mutations
Track 13: Potential role of PARP inhibitors for patients with pancreatic cancer and germline BRCA or CHEK2 mutations

Module 4: DNA Repair Deficiency in Advanced Prostate Cancer and the Potential Role of PARP Inhibition

Track 14: Consideration of PARP inhibitors for patients with PSA-only prostate cancer and germline BRCA mutations
Track 15: Emerging role of PARP inhibitors for patients with metastatic prostate cancer and BRCA mutations
Track 16: Incidence of toxicities with PARP inhibitors in patients with germline BRCA mutations
Track 17: Importance of genetic testing and appropriate selection of patients for treatment with PARP inhibitors
 
FACULTY
 
Emmanuel S Antonarakis, MD
Associate Professor of
Oncology and Urology
Johns Hopkins University
The Sidney Kimmel
Comprehensive Cancer Center
Baltimore, Maryland
 
Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Associate Director
Clinical Research
Director
Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director
Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma
Health Sciences Center
Oklahoma City, Oklahoma
 
Michael J Pishvaian, MD, PhD
Phase I Program Director
Medical Director of the CRMO
Associate Professor
Lombardi Comprehensive Cancer Center
Washington, DC
 
Melinda Telli, MD
Associate Professor of Medicine
Stanford University School of Medicine
Leader
Breast Oncology Clinical Research Group
Stanford Cancer Institute
Stanford, California
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida